A phase III study of STI-001 a biosimilar/biobetter antibody for Cetuximab in combination of irinotecan or irinotecan alone for the treatment of metastatic colorectal carcinoma
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2016
At a glance
- Drugs Cetuximab biobetter (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Jan 2016 New trial record
- 11 Jan 2016 According to a Sorrento Therapeutics media release, the primary end points (Overall Response Rate, Progressfree Survival, Overall Survival) were met.
- 11 Jan 2016 According to a Sorrento Therapeutics media release, the company announced positive data from this study.